Key points are not available for this paper at this time.
BACKGROUND: Liver cancer is a type of malignant tumor with high morbidity and mortality in People's Republic of China. Its occurrence and development involve the variation and expression changes of multiple genes, and the pathogenesis and related regulatory networks are complex. PURPOSE: In the present research, we investigate the involvement of NEAT1₂ and SFPQ in cisplatin resistance in liver cancer. The effects of LncRNA NEAT1 and SFPQ expression on the chemotherapeutic resistance of liver cancer cells were analyzed. METHODS: The expression level of NEAT1₂ and SFPQ mRNA in tissue specimens or cell lines were examined by RT-qPCR and western blotting. CCK-8 assay was performed to evaluate cell viability. Cell proliferation was performed using the EdU cell proliferation assay. RESULTS: Our data showed that increase NEAT1₂ and SFPQ expressions in liver cancer specimens were associated with the development of cisplatin resistance; high SFPQ expression level impaired patients' survival from liver cancer. Gain-and loss-of function assay using NEAT1₂ knock-in and knock-out cells constructed using CRISPER/Cas9 system revealed that NEAT1₂ is essential for liver cancer cell survival and mediates cisplatin resistance in liver cancer cells at least partially through SFPQ. Artificial change in NEAT1₂ expression level didn't significantly influence SFPQ transcription or translation level. CONCLUSION: Our data revealed NEAT1₂-SFPQ axis as a novel cisplatin resistance mechanism in liver cancer cells in vitro.
Ru et al. (Sat,) studied this question.